COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,031 Articles (22,627 medRxiv, 8,404 bioRxiv)

Most recent first Previous |  Page 1030: Articles 10291-10300  | Next

Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 2021
Eggink, D., Andeweg, S. P., Vennema, H., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A. B., van den Hof, S., Reusken, C. B. E. M., Knol, M. J.
10.1101/2021.12.20.21268121 — Posted: 2021-12-21
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
Madelon, N., Heikkila, N., Sabater Royo, I., Fontannaz, P., Breville, G., Lauper, K., Goldstein, R., Grifoni, A., Sette, A., Siegrist, C.-A., Finckh, A., Lalive, P. H., Didierlaurent, A. M., Eberhardt, C. S.
10.1101/2021.12.20.21268128 — Posted: 2021-12-21
Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., Tebeila, N., Chiwandire, N., du Plessis, M., Govender, N., Ismail, A., Glass, A., Mlisana, K., Stevens, W., Treurnicht, F. K., Makatini, Z., Hsiao, N.-y., Parboosing, R., Wadula, J., Hussey, H., Davies, M.-A., Boulle, A., von Gottberg, A., Cohen, C.
10.1101/2021.12.21.21268116 — Posted: 2021-12-21 Discussion: Onsite
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
Syed, A. M., Ciling, A., Khalid, M. M., Sreekumar, B., Kumar, G. R., Silva, I., Milbes, B., Kojima, N., Hess, V., Shacreaw, M., Lopez, L., Brobeck, M., Turner, F., Spraggon, L., Taha, T. Y., Tabata, T., Chen, I. P., Ott, M., Doudna, J. A.
10.1101/2021.12.20.21268048 — Posted: 2021-12-21
Mutational analysis of SARS-CoV-2. ORF8 and the evolution of the Delta and Omicron variants.
Trieu, G., Trieu, V. N.
10.1101/2021.12.19.21268069 — Posted: 2021-12-21
South African Population Immunity and Severe Covid-19 with Omicron Variant
Madhi, S., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A., Blumberg, L., Welch, R., Ngorima-Mabhena, N., Mutevedzi, P. C.
10.1101/2021.12.20.21268096 — Posted: 2021-12-21 Discussion: Onsite
Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
Lee, T. C., Vigod, S., Bortolussi-Courval, E., Hanula, R., Boulware, D. R., Lenze, E. J., Reiersen, A. M., McDonald, E. G.
10.1101/2021.12.17.21268008 — Posted: 2021-12-21
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant
Dolzhikova, I. V., Iliukhina, A. A., Kovyrshina, A. V., Kuzina, A. V., Gushchin, V. A., Siniavin, A. E., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Megeryan, M. M., Dzharullaeva, A. S., Erokhova, A. S., Izhaeva, F. M., Grousova, D. M., Botikov, A. G., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Logunov, D. Y., Gintsburg, A. L.
10.1101/2021.12.17.21267976 — Posted: 2021-12-21
Government messaging about COVID-19 vaccination in Canada and Australia: a Narrative Policy Framework study
Saich, F., Martiniuk, A.
10.1101/2021.12.19.21268042 — Posted: 2021-12-21
Passage of SARS-CoV-2 in cells expressing human and mouse ACE2 selects for mouse-adapted and ACE2-independent viruses
Yan, K., Dumenil, T., Le, T. T., Tang, B., Bishop, C., Suhrbier, A., Rawle, D. J.
10.1101/2021.12.16.473063 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).